Literature DB >> 24035914

15 years of genetic approaches in vivo for addiction research: Opioid receptor and peptide gene knockout in mouse models of drug abuse.

Pauline Charbogne1, Brigitte L Kieffer, Katia Befort.   

Abstract

The endogenous opioid system is expressed throughout the brain reinforcement circuitry, and plays a major role in reward processing, mood control and the development of addiction. This neuromodulator system is composed of three receptors, mu, delta and kappa, interacting with a family of opioid peptides derived from POMC (β-endorphin), preproenkephalin (pEnk) and preprodynorphin (pDyn) precursors. Knockout mice targeting each gene of the opioid system have been created almost two decades ago. Extending classical pharmacology, these mutant mice represent unique tools to tease apart the specific role of each opioid receptor and peptide in vivo, and a powerful approach to understand how the opioid system modulates behavioral effects of drugs of abuse. The present review summarizes these studies, with a focus on major drugs of abuse including morphine/heroin, cannabinoids, psychostimulants, nicotine or alcohol. Genetic data, altogether, set the mu receptor as the primary target for morphine and heroin. In addition, this receptor is essential to mediate rewarding properties of non-opioid drugs of abuse, with a demonstrated implication of β-endorphin for cocaine and nicotine. Delta receptor activity reduces levels of anxiety and depressive-like behaviors, and facilitates morphine-context association. pEnk is involved in these processes and delta/pEnk signaling likely regulates alcohol intake. The kappa receptor mainly interacts with pDyn peptides to limit drug reward, and mediate dysphoric effects of cannabinoids and nicotine. Kappa/dynorphin activity also increases sensitivity to cocaine reward under stressful conditions. The opioid system remains a prime candidate to develop successful therapies in addicted individuals, and understanding opioid-mediated processes at systems level, through emerging genetic and imaging technologies, represents the next challenging goal and a promising avenue in addiction research. This article is part of a Special Issue entitled 'NIDA 40th Anniversary Issue'.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Addiction; Drugs of abuse; Knockout mice; Opioid peptides; Opioid receptors; Reward

Mesh:

Substances:

Year:  2013        PMID: 24035914      PMCID: PMC3858501          DOI: 10.1016/j.neuropharm.2013.08.028

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  169 in total

Review 1.  Cre recombinase: the universal reagent for genome tailoring.

Authors:  A Nagy
Journal:  Genesis       Date:  2000-02       Impact factor: 2.487

2.  Isolation and structure of an untriakontapeptide with opiate activity from camel pituitary glands.

Authors:  C H Li; D Chung
Journal:  Proc Natl Acad Sci U S A       Date:  1976-04       Impact factor: 11.205

Review 3.  Review. The incentive sensitization theory of addiction: some current issues.

Authors:  Terry E Robinson; Kent C Berridge
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2008-10-12       Impact factor: 6.237

Review 4.  Psychostimulant-induced neuroadaptations in nucleus accumbens AMPA receptor transmission.

Authors:  R Christopher Pierce; Marina E Wolf
Journal:  Cold Spring Harb Perspect Med       Date:  2013-02-01       Impact factor: 6.915

Review 5.  Sensitization processes in drug addiction.

Authors:  Louk J M J Vanderschuren; R Christopher Pierce
Journal:  Curr Top Behav Neurosci       Date:  2010

6.  Genetic ablation of delta opioid receptors in nociceptive sensory neurons increases chronic pain and abolishes opioid analgesia.

Authors:  Claire Gaveriaux-Ruff; Chihiro Nozaki; Xavier Nadal; Xavier C Hever; Raphael Weibel; Audrey Matifas; David Reiss; Dominique Filliol; Mohammed A Nassar; John N Wood; Rafael Maldonado; Brigitte L Kieffer
Journal:  Pain       Date:  2011-02-03       Impact factor: 6.961

Review 7.  Nicotine and endogenous opioids: neurochemical and pharmacological evidence.

Authors:  Maria Hadjiconstantinou; Norton H Neff
Journal:  Neuropharmacology       Date:  2010-11-22       Impact factor: 5.250

8.  The human delta-opioid receptor: genomic organization, cDNA cloning, functional expression, and distribution in human brain.

Authors:  F Simonin; K Befort; C Gavériaux-Ruff; H Matthes; V Nappey; B Lannes; G Micheletti; B Kieffer
Journal:  Mol Pharmacol       Date:  1994-12       Impact factor: 4.436

Review 9.  Dual role of nicotine in addiction and cognition: a review of neuroimaging studies in humans.

Authors:  Agnes J Jasinska; Todd Zorick; Arthur L Brody; Elliot A Stein
Journal:  Neuropharmacology       Date:  2013-03-06       Impact factor: 5.250

10.  Conditional knockout of NMDA receptors in dopamine neurons prevents nicotine-conditioned place preference.

Authors:  Lei Phillip Wang; Fei Li; Xiaoming Shen; Joe Z Tsien
Journal:  PLoS One       Date:  2010-01-07       Impact factor: 3.240

View more
  64 in total

Review 1.  Non-nociceptive roles of opioids in the CNS: opioids' effects on neurogenesis, learning, memory and affect.

Authors:  Cherkaouia Kibaly; Chi Xu; Catherine M Cahill; Christopher J Evans; Ping-Yee Law
Journal:  Nat Rev Neurosci       Date:  2019-01       Impact factor: 34.870

2.  In vivo neuronal co-expression of mu and delta opioid receptors uncovers new therapeutic perspectives.

Authors:  Eric Erbs; Lauren Faget; Pierre Veinante; Brigitte L Kieffer; Dominique Massotte
Journal:  Receptors Clin Investig       Date:  2014-09

Review 3.  Genes and Alcohol Consumption: Studies with Mutant Mice.

Authors:  J Mayfield; M A Arends; R A Harris; Y A Blednov
Journal:  Int Rev Neurobiol       Date:  2016       Impact factor: 3.230

Review 4.  The opioid receptors as targets for drug abuse medication.

Authors:  Florence Noble; Magalie Lenoir; Nicolas Marie
Journal:  Br J Pharmacol       Date:  2015-06-26       Impact factor: 8.739

Review 5.  Fulfilling the Promise of "Biased" G Protein-Coupled Receptor Agonism.

Authors:  Louis M Luttrell; Stuart Maudsley; Laura M Bohn
Journal:  Mol Pharmacol       Date:  2015-07-01       Impact factor: 4.436

Review 6.  Genetic studies of alcohol dependence in the context of the addiction cycle.

Authors:  Matthew T Reilly; Antonio Noronha; David Goldman; George F Koob
Journal:  Neuropharmacology       Date:  2017-01-22       Impact factor: 5.250

7.  Impact of chronic morphine on delta opioid receptor-expressing neurons in the mouse hippocampus.

Authors:  E Erbs; L Faget; R A Ceredig; A Matifas; J-L Vonesch; B L Kieffer; D Massotte
Journal:  Neuroscience       Date:  2015-10-19       Impact factor: 3.590

Review 8.  Neuropeptidomics Mass Spectrometry Reveals Signaling Networks Generated by Distinct Protease Pathways in Human Systems.

Authors:  Vivian Hook; Nuno Bandeira
Journal:  J Am Soc Mass Spectrom       Date:  2015-10-19       Impact factor: 3.109

Review 9.  Targeting opioid dysregulation in depression for the development of novel therapeutics.

Authors:  Caroline A Browne; Irwin Lucki
Journal:  Pharmacol Ther       Date:  2019-04-30       Impact factor: 12.310

10.  Mu Opioid Receptors in Gamma-Aminobutyric Acidergic Forebrain Neurons Moderate Motivation for Heroin and Palatable Food.

Authors:  Pauline Charbogne; Olivier Gardon; Elena Martín-García; Helen L Keyworth; Aya Matsui; Anna E Mechling; Thomas Bienert; Md Taufiq Nasseef; Anne Robé; Luc Moquin; Emmanuel Darcq; Sami Ben Hamida; Patricia Robledo; Audrey Matifas; Katia Befort; Claire Gavériaux-Ruff; Laura-Adela Harsan; Dominik von Elverfeldt; Jurgen Hennig; Alain Gratton; Ian Kitchen; Alexis Bailey; Veronica A Alvarez; Rafael Maldonado; Brigitte L Kieffer
Journal:  Biol Psychiatry       Date:  2016-12-26       Impact factor: 13.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.